Stocks Rebound on Hopes Israel-Iran Conflict Will be Contained

Stock indexes are rising, recovering from Friday's selloff, driven by hopes that the Israel-Iran conflict will remain contained, while WTI crude oil prices have decreased as key Iranian oil export infrastructure remains untouched. Markets are also monitoring the G-7 meeting for potential trade and tariff developments, and bracing for upcoming economic data releases including retail sales and housing market figures, as well as the FOMC meeting where the fed funds rate is expected to remain unchanged. Chip makers and travel stocks are leading the market gains, while defensive managed care stocks are declining.

Analysis

U.S. stock indexes, including the S&P 500 (+0.79%), Dow Jones Industrials (+0.73%), and Nasdaq 100 (+0.98%), are recovering from last Friday's selloff, buoyed by hopes that the ongoing Israel-Iran conflict will not escalate further across the Middle East. This optimism has also led WTI crude oil prices to reverse earlier gains and trade lower, as critical oil export infrastructure in Iran has reportedly been spared, and the Strait of Hormuz remains open for shipping despite significant navigational signal jamming from Iran. Hostilities persist, however, with ongoing strikes by both nations, and the U.S. faces potential direct involvement if Iran targets U.S. assets or attempts to block the strait. Beyond geopolitical risks, market participants are concerned about the economic impact of potential oil price spikes and are closely watching the G-7 meeting for new trade or tariff developments, particularly following President Trump's stated intention to issue unilateral tariffs. This cautious sentiment is compounded by negative U.S. economic data, evidenced by the June Empire manufacturing survey's general business conditions index unexpectedly falling by -6.8 to -16.0, significantly weaker than the anticipated -6.0. Investor focus is now shifting to upcoming data, including May retail sales (expected -0.6% m/m), May manufacturing production (expected +0.1% m/m), and the June NAHB housing market index (expected to rise to 36). The Federal Open Market Committee (FOMC) will begin its two-day meeting on Tuesday, with markets pricing in a 0% chance of a rate cut and expecting the fed funds target range to remain at 4.25%-4.50%; attention will be on the Fed's dot-plot and Chair Powell's commentary for future policy direction. In fixed income, the 10-year T-note yield has risen +3.4 bp to 4.432%, pressured by inflation concerns linked to earlier oil price surges, weakness in European government bonds, and an upcoming $13 billion 20-year T-bond auction. Sector-wise, chip makers are broadly rallying, with AMD and ON Semiconductor up over +3%, while travel and hotel stocks like Wynn Resorts (+4%) are gaining as crude prices ease. Notable single-stock movements include Sage Therapeutics surging over +35% on an acquisition agreement with Supernus, Roku advancing over +8% following an Amazon partnership, and U.S. Steel rising over +4% on conditional approval for its acquisition by Nippon Steel. Conversely, Sarepta Therapeutics plummeted over -46% due to a patient death in a gene therapy trial and subsequent downgrades, while defensive managed care stocks such as UnitedHealth Group (-1%) are declining.

Key Decisions for Investors

• Monitor geopolitical developments in the Middle East closely, as any escalation or disruption to oil transit through the Strait of Hormuz could swiftly reverse current market optimism and impact energy prices significantly.
• Anticipate heightened market volatility around upcoming U.S. economic data releases, particularly May retail sales and manufacturing figures, and the FOMC meeting, as these will provide crucial insights into economic resilience and the Federal Reserve's policy trajectory.
• Evaluate exposure to interest rate sensitive sectors and growth stocks, given the upcoming FOMC meeting and the recent rise in T-note yields, while noting the current strength in semiconductor and travel-related equities.
• Remain vigilant regarding potential trade policy shifts, including new tariffs anticipated from the Trump administration and developments from the G-7 meeting, which could introduce headwinds for specific sectors and overall market sentiment.
• Exercise caution with individual biotech stocks facing adverse clinical trial news, such as Sarepta Therapeutics, and observe the underperformance of defensive sectors like managed care, which may indicate a short-term risk-on appetite despite underlying economic and geopolitical uncertainties.